Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 82 EV-to-OCF is 20.41 as of Aug. 10, 2026, which is 43% below its 10-year median of 35.77. GuruFocus rates VIMGF with a GF Score™ of 82/100 and a GF Value™ of $2.78. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 75.12% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vimian Group AB's Enterprise Value is $2,221.6 Mil.
Vimian Group AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $108.9 Mil. Therefore, Vimian Group AB's EV-to-OCF for today is 20.41.
The historical rank and industry rank for Vimian Group AB's EV-to-OCF or its related term are showing as below:
VIMGF'
s EV-to-OCF Range Over the Past 10 Years
Min: -86.43 Med: 35.77 Max: 487.83
Current: 20.84
During the past 9 years, the highest EV-to-OCF of Vimian Group AB was 487.83. The lowest was -86.43. And the median was 35.77.
VIMGF's EV-to-OCF is ranked worse than 75.12% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.35
vs VIMGF: 20.84
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vimian Group AB (OTCPK:VIMGF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vimian Group AB's PE Ratio (TTM) for today is calculated as:
Vimian Group AB's share price for today is $2.77.
Vimian Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.081.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vimian Group AB EV-to-OCF Related Terms
Vimian Group AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's EV-to-OCF falls into.
Vimian Group AB's current Enterprise Value is $2,221.6 Mil.
Vimian Group AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $108.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a EV-to-OCF of 20.41 as of Aug. 10, 2026. This is 43% below median its historical median of 35.77. According to the industry distribution chart, Vimian Group AB ranks #160 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 75.1%.
Is Vimian Group AB's EV-to-OCF too high?
Vimian Group AB's current EV-to-OCF of 20.41 is 43% below median its 10-year median of 35.77. The Medical Diagnostics & Research industry median EV-to-OCF is 6.35. Vimian Group AB's value of 20.41 is 221.4% above this industry median. Based on the distribution chart, Vimian Group AB ranks #160 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vimian Group AB has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #160 out of 213 companies for EV-to-OCF. This places Vimian Group AB in the lower half of its industry. The industry median EV-to-OCF is 6.35. Vimian Group AB's value of 20.41 is 221.4% above this benchmark. While the company's 10-year median is 35.77 vs. the industry median of 6.35, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.35, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current EV-to-OCF of 20.41 is 221.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current EV-to-OCF is 20.41, which is 43% below median its own 10-year median of 35.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current EV-to-OCF of 20.41. The stock's GF Value™ is $2.78, compared to a current price of $2.77 — trading 0.4% below its estimated fair value. The current EV-to-OCF is 20.41, which is 43% below median its 10-year median of 35.77 and 221.4% above the Medical Diagnostics & Research industry median of 6.35. Vimian Group AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current EV-to-OCF is 20.41 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 0.4% below its estimated GF Value™ of $2.78.
Key valuation signals for VIMGF:
EV-to-OCF: 20.41 (43% below median its 10-year median of 35.77)
GF Value™: $2.78 vs. price of $2.77 (0.4% below fair value)
Industry Position: 221.4% above the Medical Diagnostics & Research median (#160 of 213)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
82GF Score
Get the complete analysis for VIMGF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
